![]() ![]() I didn't have any specific goals aside from it being first person and being able to see rolling raindrops on a glossy, transparent surface. Several environments I've been working on for the project have a rainy atmosphere, Inspired by several rainy walks I'd done, I decided that a useable umbrella in the game would be a nice addition. Since the game is such an open concept, that's why I've been working on fun, experimental ideas such as the first-person umbrella. It'll be released as a game, but I see it more as a way to showcase my work in 3D environment art in a format that allows people to explore and walk around. The "Photography Sim" project I've been doing has sort of been the eventuation of all the various freelance projects I've been working on. Before I took the plunge with UE, I had a strong background in photography and color design, as opposed to game development. ![]() Because UE, is so versatile I've been able to work in fields like Live Music, Live Streaming, Film, App development for museums, interactive films, and VR. ![]() During my time studying, I couldn't commit to any full-time positions so I undertook a lot of freelance Unreal Engine work doing Environment/Tech Art and blueprint scripting. My name is Matt, I'm from Perth in West Australia where I was studying computer systems engineering right up until last month. You can check out our interview with the developer down below and learn more about the shader by clicking this link. For more information, visit follow us on and LinkedIn.Luckily, Matt agreed to tell us more about the shader, explaining how the transparency and refraction were set up, sharing some insights about the droplets, and discussing the optimization process. In addition, we are globally advancing multiple programs for systemic mastocytosis, lung cancer, breast cancer, and other genomically defined cancers, and cancer immunotherapy. Today, we are delivering our approved medicines to patients in the United States, Europe, and in other geographies ourselves or through our partners. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate our scientific innovation into a broad pipeline of important approved and investigational precision therapies aimed at addressing difficult-to-treat cancers and blood disorders. ![]() Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. The options and RSUs are subject to the terms and conditions of Blueprint Medicines' 2020 Inducement Plan, and the terms and conditions of the stock option and RSU agreement covering the grant.īlueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Each RSU will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the RSU award annually thereafter, subject to each such employee's continued employment on each vesting date. Each option will vest as to 25% of the shares underlying such option on the first anniversary of the grant date and as to an additional 1/48th of the shares underlying the option monthly thereafter, in each case, subject to each such employee's continued employment on each vesting date. The options have an exercise price of $65.89 per share, which is equal to the closing price of Blueprint Medicines' common stock on September 30, 2022. The 2020 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Blueprint Medicines, as an inducement material to such individual's entering into employment with Blueprint Medicines, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. 6, 2022 /PRNewswire/ - Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective October 1, 2022, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 11,381 shares of its common stock and an aggregate of 5,688 restricted stock units (RSUs) to eight new employees under Blueprint Medicines' 2020 Inducement Plan. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |